Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi Biosciences's Tuoyi is First China-Developed Anti-PD-1 Drug Approved for Marketing

publication date: Dec 19, 2018

Junshi Biosciences of Shanghai announced Tuoyi (toripalimab), its anti-PD-1 checkpoint inhibitor, was approved in China as a second-line treatment for melanoma, the first domestic PD-1 approved in China. There are three other China-developed anti-PD-1 mAbs under review by the NMPA. Tuoyi joins two US already-China-approved PD-1 products in the market: Keytruda from Merck and Opdivo from Bristol-Myers Squibb. Junshi is completing a $400 million IPO on the Hong Kong Exchange. More details....

Stock Symbols: (NYSE: MRK) (NYSE: BMY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.